Skip to main content
Patient-reported outcomes data on health-related quality of life
Navbar Image
Patient-reported outcomes data on health-related quality of life
This site is intended only for US healthcare professionals.

Patient-reported outcomes data on health-related quality of life

SLOWER DECLINE IN HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS RECEIVING COSELA IN A POOLED ANALYSIS

Patient-reported outcomes data were descriptive and exploratory study endpoints in the three clinical studies to measure the effects of COSELA on health-related quality of life. Patient-reported outcomes were assessed under certain endpoints, such as anemia and fatigue. Outcomes measures were not validated in the study population; therefore, no conclusions can be drawn.

  • COSELA was proactively given before etoposide/carboplatin/atezolizumab or etoposide/carboplatin in first-line treatment of ES-SCLC and before topotecan in second- or third-line treatment1
  • Retrospective pooled analysis of exploratory endpoints across three studies1
  • In treatment groups receiving COSELA, the most common adverse reactions (≥10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia
See the Study Design
Chemotherapy regimen arm=placebo+etoposide /carboplatin/atezolizumab or etoposide/carboplatin or topotecan.
a
Confirmed deterioration was defined as a decrease from baseline by a clinically meaningful threshold for 2 consecutive visits: ≤3 points for physical wellbeing, functional wellbeing, and fatigue; ≤6 points for anemia trial outcome index points; and ≤7 points for Functional Assessment of Cancer Therapy–Anemia scores.1
Caution should be taken when interpreting pooled analysis data, because differences in the patient population and chemotherapy backbones exist across the three individual studies.